Vaxxinity, Inc.: management transactions · United States · SEC (Form 4)

About Vaxxinity, Inc.

Vaxxinity, Inc. is a United States-based biotechnology company listed on the NASDAQ under the ticker VAXX. The company is headquartered in Dallas, Texas, United States, with its public business address shown at 2622 Commerce St., Dallas, TX 75226. Vaxxinity describes itself as a developer of next-generation immunotherapeutic vaccines and antibody-inducing medicines aimed at chronic diseases rather than only traditional infectious-disease vaccination. ([vaxxinity.com](https://vaxxinity.com/?utm_source=openai)) Historically, Vaxxinity emerged from the United Biomedical ecosystem and was built around the idea of commercializing a synthetic-peptide vaccine approach at scale. Management positions the company as a platform biotech designed to create medicines that harness the immune system to generate antibodies, with an emphasis on affordability, stability, and manufacturability. The company’s official science materials state that its AIM (Active Immunotherapy Medicine) platform uses synthetic peptides to selectively activate the immune system and that the platform has been validated through animal-health use and multiple human clinical trials. ([vaxxinity.com](https://vaxxinity.com/our-science/?utm_source=openai)) From an operating perspective, Vaxxinity is primarily a clinical-stage company. It does not rely on a broad commercial portfolio of marketed products; instead, value creation is tied to a pipeline of investigational assets. Its main programs include UB-311 for Alzheimer’s disease, UB-312 targeting aggregated alpha-synuclein for Parkinson’s disease and related synucleinopathies, VXX-401 for lowering LDL cholesterol via PCSK9 biology, and a COVID-related program built around a multitope immune response. This gives Vaxxinity exposure to several large therapeutic markets, but also makes the investment case highly dependent on clinical outcomes and regulatory progress. ([vaxxinity.com](https://vaxxinity.com/our-pipeline/?utm_source=openai)) In competitive terms, Vaxxinity differentiates itself through a synthetic peptide platform and a value proposition centered on cold-chain practicality and scalable manufacturing. The company emphasizes that some of its candidates can be stored and shipped at conventional 2–8°C temperatures, which could be advantageous if later-stage development succeeds and commercialization becomes possible. That said, it competes in highly crowded and scientifically demanding fields, including neurology, cardiovascular disease, and infectious disease, where large-cap pharma and well-funded biotech peers have materially greater resources. ([vaxxinity.com](https://vaxxinity.com/our-science/?utm_source=openai)) Geographically, Vaxxinity is a U.S. company with an international development footprint, but its corporate identity, listing venue, and headquarters are clearly American. For investors in France, Belgium, and Switzerland, VAXX should be viewed as a NASDAQ-listed biotech with asymmetric upside potential but substantial execution risk. Recent company messaging continues to highlight pipeline advancement, especially in Alzheimer’s and Parkinson’s-related programs, underscoring that the near-term equity story is still driven by research progress rather than product revenue. ([vaxxinity.com](https://vaxxinity.com/?utm_source=openai))